San Diego-based Metabasis Therapeutics reported this morning that the firm's President, CEO, and Chief Scientific Officer, Mark Erion, is leaving the firm. According to Metabasis, Erion is leaving the firm for Merck, to become Vice President and Worldwide Basic Franchise head of Diabetes and Obesity at that company. Erion also resigns as diriector of the company. Metabasis said that David Hale takes over as executive chairman. The company is developing drugs for treating metabolic diseases.
Top NewsTuesday, September 1, 2009
Metabasis Therapeutics Loses CEO